CA3180564A1 - Compositions and methods comprising clostridium butyricum for the treatment of cancer - Google Patents

Compositions and methods comprising clostridium butyricum for the treatment of cancer

Info

Publication number
CA3180564A1
CA3180564A1 CA3180564A CA3180564A CA3180564A1 CA 3180564 A1 CA3180564 A1 CA 3180564A1 CA 3180564 A CA3180564 A CA 3180564A CA 3180564 A CA3180564 A CA 3180564A CA 3180564 A1 CA3180564 A1 CA 3180564A1
Authority
CA
Canada
Prior art keywords
cancer
dose
clostridium butyricum
cfu
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3180564A
Other languages
English (en)
French (fr)
Inventor
Peter P. Lee
Sumanta Kumar PAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CA3180564A1 publication Critical patent/CA3180564A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3180564A 2020-04-21 2021-04-20 Compositions and methods comprising clostridium butyricum for the treatment of cancer Pending CA3180564A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013141P 2020-04-21 2020-04-21
US63/013,141 2020-04-21
PCT/US2021/028251 WO2021216618A1 (en) 2020-04-21 2021-04-20 Compositions and methods comprising clostridium butyricum for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3180564A1 true CA3180564A1 (en) 2021-10-28

Family

ID=78270016

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3180564A Pending CA3180564A1 (en) 2020-04-21 2021-04-20 Compositions and methods comprising clostridium butyricum for the treatment of cancer

Country Status (8)

Country Link
US (1) US12589123B2 (enExample)
EP (1) EP4138869A4 (enExample)
JP (2) JP7813240B2 (enExample)
KR (1) KR20230004604A (enExample)
CN (1) CN116390737A (enExample)
AU (1) AU2021261290A1 (enExample)
CA (1) CA3180564A1 (enExample)
WO (1) WO2021216618A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240415900A1 (en) * 2021-10-20 2024-12-19 City Of Hope Clostridium butyricum compositions and methods of using the same
CN115671142A (zh) * 2022-11-15 2023-02-03 中山大学附属第六医院 丁酸梭菌在结直肠癌辅助治疗上的应用
CN116650534B (zh) * 2023-03-10 2026-07-28 中南大学 丁酸梭菌及其细菌外囊泡在制备治疗多发性骨髓瘤或复发难治多发性骨髓瘤制剂中的应用
CN121152637A (zh) * 2023-05-23 2025-12-16 日本米雅利桑制药株式会社 癌治疗用组合药物
CN116687979B (zh) * 2023-06-28 2025-06-20 中国人民解放军陆军军医大学 肠道微生物在稳定肠道谷氨酰胺以及在制备治疗癌症的药物中的应用
CN120131715A (zh) * 2025-03-14 2025-06-13 中山大学孙逸仙纪念医院 膀胱灌注丁酸梭菌免疫制剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6153219A (ja) 1984-08-23 1986-03-17 Tadashi Arai 抗腫瘍剤
JP2009269836A (ja) 2008-05-01 2009-11-19 Miyarisan Pharmaceutical Co Ltd 大腸癌細胞増殖抑制物質
EP3518946A4 (en) * 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
EP3559257A1 (en) 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
WO2019165285A1 (en) * 2018-02-23 2019-08-29 Crestovo Holdings Llc Microbiome related immunotherapies
WO2019178542A1 (en) * 2018-03-16 2019-09-19 Persephone Biome, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
CN109771445B (zh) 2019-03-20 2022-08-05 青岛东海药业有限公司 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用

Also Published As

Publication number Publication date
JP2026031928A (ja) 2026-02-25
CN116390737A (zh) 2023-07-04
US12589123B2 (en) 2026-03-31
EP4138869A4 (en) 2024-05-15
JP2023522716A (ja) 2023-05-31
US20230149479A1 (en) 2023-05-18
EP4138869A1 (en) 2023-03-01
KR20230004604A (ko) 2023-01-06
AU2021261290A1 (en) 2022-11-03
JP7813240B2 (ja) 2026-02-12
WO2021216618A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US12589123B2 (en) Compositions and methods comprising clostridium butyricum for the treatment of cancer
US20210364520A1 (en) Depleting tumor-specific tregs
US20210346438A1 (en) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
AU2014351348A1 (en) Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
WO2016063263A2 (en) Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
KR20220116438A (ko) 암 치료를 위한 미생물총 및 대사산물의 힘 활용
JP7750871B2 (ja) 治療用細菌組成物
CN115175575A (zh) 设计的细菌组合物及其用途
BR112020014446A2 (pt) Métodos para administrar imunoterapia de receptor de antígeno quimérico em combinação com agonista de 4-1bb
EP3810279B1 (en) A combination comprising using an oligopeptidic compound and anti-pd-1 or pd-l1 antibody for use in treating neoplastic conditions
US12629396B2 (en) Application of bacteria in preparation of synergist for immune checkpoint inhibitor
WO2025162252A1 (zh) 防治弥漫大b细胞淋巴瘤的甲磺酸普依司他及其类似物、联合用药物及用途
WO2025072639A1 (en) Methods of treating cancer resistant to immune checkpoint therapy and compositions useful for the same
JP2022517268A (ja) 免疫チェックポイント阻害剤関連大腸炎を処置するための方法および組成物
WO2023069655A1 (en) Clostridium butyricum compositions and methods of using the same
Di Modica Gut microbiota and trastuzumab response in HER2-positive breast cancer

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250226

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250226

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250415

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250415

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250417

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250417

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250417

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250616

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250616

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250616

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250616

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250616